
-
Gezora wins Prix de Diane in Graffard masterpiece
-
Pogacar wins first Dauphine ahead of Tour de France title defence
-
Trump due in Canada as G7 confronts Israel-Iran crisis
-
Kubica steers Ferrari to third consecutive 24 Hours of Le Mans
-
French Open champ Alcaraz ready for Queen's after Ibiza party
-
India a voice for Global South at G7, says foreign minister
-
Sinner had 'sleepless nights' after dramatic French Open final loss
-
Gattuso named new Italy coach after Spalletti sacking
-
Relatives lament slow support, wait for remains after India crash
-
Israel vows to make Iran pay 'heavy price' as fighting rages on
-
Macron, on Greenland visit, berates Trump for threats against the territory
-
Qualifier Maria completes fairytale run to Queen's title
-
Gattuso named new Italy coach
-
Tens of thousands rally in Dutch Gaza protest
-
Israel-Iran conflict: latest developments
-
Israel keeps up Iran strikes after deadly missile barrage
-
Ex-president Sarkozy stripped of France's top honour after conviction
-
Iran missiles kill 10 in Israel in night of mutual attacks
-
'This is a culture': TikTok murder highlights Pakistan's unease with women online
-
Families hold funerals for Air India crash victims
-
US Fed set to hold rates steady in the face of Trump pressure
-
Sober clubbing brews fresh beat for Singapore Gen Z
-
Cummins flags Australia shake-up after WTC defeat as Ashes loom
-
Mexico down Dominican Republic to open Gold Cup defence
-
Pochettino defends Pulisic omission: 'I'm not a mannequin'
-
Panthers on brink of Stanley Cup repeat after 5-2 win over Oilers
-
Messi denied late winner in Club World Cup opener
-
Trump flexes military might at parade as protests sweep US
-
New-look Man City crave winning feeling at Club World Cup
-
Big tech on a quest for ideal AI device
-
Guest list for G7 summit tells of global challenges
-
Macron to Greenland in show of support after Trump threats
-
'Mass grave' excavation to finally start at Irish mother and baby home
-
'Hidden treasure': Rare Gandhi portrait up for UK sale
-
Fearless Chiefs plot raid on Crusaders fortress in Super Rugby final
-
US Open leader Burns eyes first major title at historic Oakmont
-
Messi gets Club World Cup under way in Miami
-
Burns grabs US Open lead with Scott and Spaun one back
-
Future of Uncrewed Airpower on Display at Paris Air Show
-
Russell grabs dazzling Canadian GP pole then jokes at Verstappen's expense
-
Thompson in six-way tie for LPGA lead in Michigan
-
Inter striker Taremi stranded in Iran amid conflict: club
-
No.1 Scheffler well back as pal Burns fights for US Open title
-
Trump's military parade kicks off as protests sweep US
-
PSG excitement for Club World Cup trumps fatigue ahead of Atletico clash
-
Burns and Spaun share US Open lead through nine holes of third round
-
Toulon power past Castres and into Top 14 semi-final
-
Russell delivers sensational lap to take pole at Canadian GP
-
Anti-Trump protesters rally across US ahead of military parade
-
Iran activates air defences, Israelis told to shelter as both sides trade strikes

Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
O.Krause--BTB